MicroIslet Announces Human Islet Transplantation Studies at the University of Alberta, Edmonton
December 16 2004 - 8:00AM
PR Newswire (US)
MicroIslet Announces Human Islet Transplantation Studies at the
University of Alberta, Edmonton SAN DIEGO, Dec. 16
/PRNewswire-FirstCall/ -- MicroIslet, Inc. (AMEX:MII) announced
today an expanded research collaboration with the University of
Alberta, Edmonton in the area of human islet cell transplantation
therapies for treatment of insulin-dependent diabetes. Under the
terms of the agreement, MicroIslet and University of Alberta
scientists will conduct animal studies utilizing MicroIslet's
proprietary technologies for encapsulating islet cells that have
been isolated from human cadavers. MicroIslet's management believes
the successful completion of these joint studies is a prerequisite
for future clinical pilot studies of its encapsulation technology
in humans. MicroIslet and University of Alberta scientists are
hopeful that the work will be another important step in minimizing
the need for immunosuppression in patients who undergo the
transplantation of insulin-producing islet cells under the Edmonton
Protocol. The work in Edmonton will be conducted by a group led by
Dr. James Shapiro and Dr. Jonathan Lakey, pioneering scientists in
the field of human islet transplantation and key leaders of the
team that developed the Edmonton Protocol. As part of this
collaboration, MicroIslet will provide financial support and
technical assistance to the Edmonton team. The University of
Alberta will contribute significant resources, including the
transplantation expertise of its scientists and access to its
facilities. This project will be conducted in parallel with
MicroIslet's ongoing studies using encapsulated pig islet cells
(xenotransplantation) at The Scripps Research Institute in La
Jolla, California, and the California Regional Primate Center at
the University of California, Davis. About MicroIslet MicroIslet is
a biotechnology company engaged in the research, development, and
commercialization of patented technologies in the field of
transplantation therapy for people with insulin-dependent diabetes.
MicroIslet's patented islet transplantation technology, exclusively
licensed from Duke University, includes methods for isolating,
culturing, cryopreservation, and immuno-protection
(microencapsulation) of islet cells. MicroIslet is working to
develop and commercialize a first product, called MicroIslet-P, a
microencapsulated porcine islet cell suspension that will be used
for transplantation in patients with insulin-dependent diabetes.
Additional information about MicroIslet can be found at
http://www.microislet.com/. Except for the historical information
contained herein, the matters set forth in this press release,
including the expectation of development of new therapeutic
products, and the impact of MicroIslet's products on diabetes
patients, are forward-looking statements within the meaning of the
"safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are subject to
risks and uncertainties that may cause actual results to differ
materially, including the risks and uncertainties inherent in
medical treatment discovery, development and commercialization, the
risks and uncertainties associated with MicroIslet's early stage
xenotransplantation technologies, the risks and uncertainties of
governmental approvals and regulation, MicroIslet's need to raise
substantial additional capital to proceed through human clinical
trials and bring any product to market, the risks that MicroIslet's
competitors will develop or market technologies or products that
are more effective or commercially attractive than MicroIslet's
products, and other risks detailed from time to time in
MicroIslet's most recent filings with the Securities and Exchange
Commission. These forward-looking statements speak only as of the
date hereof. MicroIslet disclaims any intent or obligation to
update these forward-looking statements. For more information,
please visit our Web site at http://www.microislet.com/. For
further information, contact: Haro Hartounian, Ph.D. President and
Chief Operating Officer, MicroIslet Inc. +1-858-657-0287, Jonathan
Lakey, Ph.D. Professor of Surgery, University of Alberta, Edmonton
+1-780-492-3077, , http://www.ualberta.ca/ DATASOURCE: MicroIslet
Inc. CONTACT: Haro Hartounian, Ph.D., President and Chief Operating
Officer, MicroIslet Inc., +1-858-657-0287, ; or Jonathan Lakey,
Ph.D., Professor of Surgery, University of Alberta, Edmonton,
+1-780-492-3077, Web site: http://www.ualberta.ca/ Web site:
http://www.microislet.com/
Copyright
Microislet (AMEX:MII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Microislet (AMEX:MII)
Historical Stock Chart
From Jul 2023 to Jul 2024